Voyager Therapeutics reported a quarterly loss of $0.46 per share for Q4 2025, beating the Zacks Consensus Estimate of a loss of $0.54 per share. This represents an earnings surprise of 15.08% and compares to a loss of $0.59 per share in the same quarter last year. The gene therapy company posted revenues of $15.34 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 57.97%. This compares to year-ago revenues of $6.28 million. The company has topped consensus revenue estimates twice over the last four quarters. Voyager shares have declined 0.8% since the beginning of the year, outperforming the S&P 500's 1.5% decline. The company currently holds a Zacks Rank 3 (Hold), suggesting shares are expected to perform in line with the market.

Voyager Therapeutics reported fourth quarter and full year 2025 financial results, ending the year with a cash position of $202 million expected to maintain operations into 2028. The company anticipates 2026 will be pivotal, with clinical entry for tau-targeting Alzheimer's therapies VY1706 and VY7523 expected in the second half. Collaboration revenue reached $15.3 million in Q4 2025, up from $6.3 million in Q4 2024, though full-year revenue declined to $40.4 million from $80 million. Net loss for 2025 was $119.7 million compared to $65 million in 2024. Voyager expects to dose its first patient with VY1706 in H2 2026 and release tau PET imaging data for VY7523 during the same period. Partner Neurocrine plans to initiate clinical trials for Friedreich's ataxia therapy NBIB-'223 in H2 2026, pending FDA approval.

Voyager jettisons 30 employees, Novartis hands back rights to 2 programs. Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company confirmed to Fierce Biotech. The layoffs come after the November announcement, tucked in Voyager's third-quarter earnings report, that Novartis has discontinued two discovery-stage programs from the pair's ongoing team-up, returning the rights to Voyager. Programs for Huntington's disease, spinal muscular atrophy and another undisclosed target were unaffected by the decision, Voyager said at the time. "Voyager evaluates its business needs on an ongoing basis to ensure it has the appropriate workforce and expertise to support its business goals," the spokesperson explained Wednesday. At the time of publication, Voyager had not responded to Fierce's questions about the number of employees left at the company or whether the layoffs are related to Novartis' decision to discontinue the programs. The biotech employs between 51 and 200 people, according to its LinkedIn page. Voyager has one clinical asset, a tau-targeting antibody in a phase 1 study for Alzheimer's disease. The biotech plans to launch another asset, a tau-silencing small interference RNA molecule called VY1706, into clinical trials next year, according to Voyager's third-quarter earnings report. The company is also pursuing a gene therapy for amyotrophic lateral sclerosis but had to delay its efforts on that front earlier this year to find a new payload. Also in November, Voyager took off on a new research collaboration with Transition Bio to discover and develop small molecules for neurodegenerative diseases. Voyager paid its new partner a single-digit million-dollar upfront payment, with additional payments up to $500 million possible if certain milestones are met. As of Sept. 30, Voyager had $229 million stored in its cargo, according to the earnings report.